Urovan­t's over­ac­tive blad­der drug scores in mid-stage tri­al

Urovant Sci­ences said its ex­per­i­men­tal over­ac­tive blad­der drug vibegron im­proved symp­toms in a large mid-stage study, a wel­come sig­nal for the com­pa­ny as it eval­u­ates …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER